SCHEMBL3518804

SCHEMBL3518804

O=C(O)CNC(=O)c1c(O)c(-c2cccs2)cc2nc(-c3cccs3)cnc12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGLN3 Q9H6Z9 3/20 0.52
KDM4E B2RXH2 5/20 0.42
ALDH1A1 P00352 4/20 0.42
GAA P10253 4/20 0.42
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
HPGD P15428 2/20 0.41
CASP1 P29466 1/20 0.41
MAPK10 P53779 1/20 0.41
CASP7 P55210 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HSD17B10 Q99714 1/20 0.41
GLA P06280 1/20 0.40
THRB P10828 1/20 0.40
KAT8 Q9H7Z6 1/20 0.40
HPGDS O60760 2/20 0.39
ATM Q13315 1/20 0.39
POLB P06746 1/20 0.38
MAPT P10636 1/20 0.38
EGLN1 Q9GZT9 3/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3763139 0.93 EGLN3 (0.54) EGLN3KDM4EALDH1A1GAAHPGD
SCHEMBL3755841 0.90 EGLN3 (0.46) EGLN3KDM4EALDH1A1GAANPC1
SCHEMBL3520062 0.89 EGLN3 (0.49) EGLN3KDM4EALDH1A1GAANPC1
SCHEMBL3519157 0.88 EGLN3 (0.47) EGLN3KDM4EALDH1A1GAAKAT8
SCHEMBL3520971 0.87 NPC1 (0.41) EGLN3KDM4EALDH1A1GAANPC1
SCHEMBL3520863 0.85 EGLN3 (0.52) EGLN3KDM4EALDH1A1GAANPC1
SCHEMBL3517885 0.85 EGLN3 (0.67) EGLN3KDM4EALDH1A1NPC1RAB9A
SCHEMBL3517411 0.85 KDM4E (0.48) KDM4EALDH1A1GAANPC1RAB9A
SCHEMBL3756004 0.82 EGLN3 (0.42) EGLN3KDM4EALDH1A1GAANPC1
SCHEMBL3520368 0.81 EGLN3 (0.64) EGLN3EGLN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 US claimed
EP-2227770-A2 PROLYL HYDROXYLASE INHIBITORS GlaxoSmithKline LLC (US) 2010-09-15 EP claimed
WO-2009073497-A2 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-11 WO claimed
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 US disclosed
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 US disclosed
US-20100305133-A1 Prolyl Hydroxylase Inhibitors SMITHKLINE BEECHAM CORPORATION 2010-12-02 US disclosed
EP-2227770-A2 PROLYL HYDROXYLASE INHIBITORS GlaxoSmithKline LLC (US) 2010-09-15 EP disclosed
WO-2009073497-A2 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-11 WO disclosed
WO-2009073497-A2 PROLYL HYDROXYLASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2009-06-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305133-A1 Prolyl Hydroxylase Inhibitors HIF1AN, EGLN3, EGLN2 EGLN3 2/4885KDM4E 176/4885ALDH1A1 191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.